NASOPHARYNGEAL CARCINOMA

This study tests whether adding a new drug (toripalimab) to standard chemotherapy before radiation can safely and effectively treat a type of throat cancer caused by the Epstein-Barr virus. About 24 adults with advanced but non-spread cancer will receive three cycles of the drug …

This study tests a one-year maintenance treatment combining tislelizumab (an immunotherapy) and low-dose capecitabine (a chemotherapy) in 53 adults with high-risk nasopharyngeal cancer. Participants have a specific marker (detectable EBV DNA) after initial chemotherapy, indicatin…

This study looks at whether giving a lower dose of radiation after a good response to initial chemotherapy is as effective as the standard higher dose for people with Epstein-Barr virus (EBV)-related nasopharyngeal cancer. The goal is to reduce long-term side effects like hearing…

This study tests whether adding a new immunotherapy drug (cadonilimab) and low-dose radiation to standard chemotherapy can help people with advanced nasopharyngeal cancer live longer without the cancer coming back. About 380 adults aged 18-70 with newly diagnosed, advanced cancer…

This phase 3 trial tests whether adding an immunotherapy drug (anti-PD-1 antibody) to standard chemoradiotherapy helps people with nasopharyngeal cancer that has come back after initial treatment. About 212 adults whose cancer cannot be surgically removed will be randomly assigne…

This study looks at whether people with stage III nasopharyngeal cancer whose tumors respond well to initial treatment can safely receive a lower dose of radiation. About 593 participants will get either standard or reduced radiation, plus chemotherapy and immunotherapy. The goal…

This study tests whether a structured nutrition plan helps patients with advanced nasopharyngeal cancer who are already malnourished. About 266 adults aged 18-65 will be randomly assigned to receive either standard nutrition therapy or conventional nutrition advice during their c…

This phase 3 trial tests whether adding toripalimab (an immunotherapy) to capecitabine (a chemotherapy pill) as maintenance therapy works better than capecitabine alone for people with high-risk nasopharyngeal carcinoma. The study enrolls 264 adults aged 18-70 who have completed …

This study compares a lower dose of radiation (40.2Gy) to the standard dose (49.2Gy) for people with stage II nasopharyngeal cancer that responds well to chemotherapy and immunotherapy. The goal is to see if the lower dose can control the cancer just as well while causing fewer s…

This study tests whether adding targeted radiation to an immunotherapy drug (camrelizumab) helps control cancer better than the drug alone in people with nasopharyngeal cancer that has spread to a few other spots. About 188 adults whose original tumor is under control and who hav…

This study tests whether adding the drug envafolimab to standard chemoradiation and another drug (endostatin) can better shrink tumors in people with advanced nasopharyngeal cancer. About 30 adults aged 18-65 with stage III-IVA disease will receive the combination. The main goal …

This early-phase study tests two types of specially engineered immune cells (CAR-T and TCR-T) that target the Epstein-Barr virus (EBV) in patients with nasopharyngeal cancer that has come back or not responded to treatment. About 24 adults will receive one of the two cell therapi…

This study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain cancers (like head and neck, brain, or kidney tumors) that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug i…

This study tests a new treatment for people whose nasopharyngeal cancer has come back or spread. It combines two types of radiation with immunotherapy and chemotherapy. The goal is to see if this mix can control the cancer longer and with manageable side effects. About 148 adults…

This study tests a combination of two drugs (BL-B01D1 and a PD-1 antibody) in adults with advanced or spreading non-small cell lung cancer, nasopharyngeal cancer, or other solid tumors. The goal is to see if the combo can shrink tumors and control the disease. About 570 participa…

This study is testing a new two-drug combination (BL-B01D1 + SI-B003) for people with advanced non-small cell lung cancer or nasopharyngeal carcinoma that has spread. The main goal is to see if the treatment is safe and if it shrinks tumors. Researchers will enroll about 121 adul…

This study tests a new type of PET/CT scan that looks for a protein called CD70 on cancer cells. It aims to better detect kidney cancer, lymphoma, and nasopharyngeal cancer in 300 adults. The scan may help doctors see tumors more clearly and guide treatment decisions.

This study tests whether giving radiation only to the specific neck areas where cancer has spread can reduce side effects and improve quality of life for people with nasopharyngeal cancer, without lowering survival chances. About 470 newly diagnosed patients will be assigned to e…

This study looks at 50 people with nasopharyngeal cancer that has come back or spread. Researchers want to see if advanced lab tests (multi-omics) can predict how well a combination of chemotherapy, radiation, and immunotherapy will work. The goal is to find better ways to person…